Regulatory Roundup: EMA monitors Japanese-manufactured medicines following radiation leak from nuclear power plant - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: EMA monitors Japanese-manufactured medicines following radiation leak from nuclear power plant

ePT--the Electronic Newsletter of Pharmaceutical Technology

EMA is working with its European and international regulatory partners to monitor and evaluate “the possible risk of radioactive contamination of medicines manufactured in Japan following the radiation leak from the Fukushima Daiichi nuclear power plant,” according to a recent EMA press release. To date, information has shown that the risk to public and animal health is small, but EMA is taking a precautionary approach, which includes putting certain measures into place for food and animal feed throughout Europe. The ultimate responsibility for safety, efficacy, and quality of products manufactured in Japan, says the release, is the holder of the product marketing authorization. Marketing authorization holders are therefore being asked to test their products for radionuclides iodine-131, caesium-134, and caesium-137 prior to exporting products out of Japan.

FDA has posted on its website the minutes from meetings between the agency and industry regarding the Prescription Drug User Fee Act (PDUFA) reauthorization. The meetings took place in January and February of this year.

FDA and EMA released on May 16, 2011, a document about how the agencies plan to work together on parallel reviews of quality-by-design based new drug applications as part of their ongoing pilot program. The document provides advice to applicants on the background and objectives of the pilot, as well on the steps that will be taken to coordinate the parallel review and related GMP inspections.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here